The Effect of Oral Royal Jelly on Clinical Disease Activity Index (CDAI) and Morning Stiffness in Patients with Rheumatoid Arthritis (RA); A Randomized Double-Blind, Placebo-Controlled Trial

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Rheumatology, School of Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran

2 Resident, Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

3 Professor, Depertment of Pharmacology, School of Medicine, Shahrekord University Of Medical Sciences, Shahrekord, Iran

4 Lecturer, Department of Nursing, School of Nursing and Midwifery, Shahrekord University Of Medical Sciences, Shahrekord, Iran

5 General Practitioner, Shahrekord, Iran

Abstract

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease which can cause articular destruction and disability in patients. Current therapies are relatively effective and sometimes harmful. Royal Jelly with anti-inflammatory and anti-oxidative properties may be used as an adjunct therapy. The aim of this study was to assess the effect of Royal Jelly on Clinical Disease Activity Index (CDAI) and morning stiffness in patients with rheumatoid arthritis.Methods: According to American College of Rheumatology (ACR) 1987 classification criteria, 80 patients with RA, who had active disease (CDAI > 2.8), were randomly assigned to receive Royal Jelly or placebo beside background treatment for 3 months. Morning stiffness, tender joint count (TJC), swollen joint count (SJC), evaluator global assessment (EGA) and patient’s global assessment (PGA) [based on visual analogue scale (VAS)] were determined before and after 3 months of intervention. The changes in aforementioned indexes were analyzed by SPSS software.Findings: 65 patients completed the study (35 in Royal Jelly and 30 in placebo group). The sex, age, residence, disease duration and drug consumption had no significant changes (P > 0.050). In the first group, CDAI (P = 0.012), SJC (P = 0.024), TJC (P = 0.027), and morning stiffness (P = 0.004) had significant statistical changes; but only changes in morning stiffness were statistically different between the two groups (P < 0.05).Conclusion: Royal Jelly has good effect on morning stiffness but not on CDAI and may be a suitable adjunct therapy. Further studies may demonstrate more significant results.

Keywords

References

  1. Firestein GS. Rheumatoid arthritis. In: Harris E, Budd R, Firestein GS, editors. Kelly's text book of rheumatology. 7th ed. Philadelphia, PA: Saunders; 2004.
  2. Odeh M. Short analytical review: new insights into the pathogenesis and treatment of rheumatoid arthritis. Clin Immunol Immunopathol 1997; 83(2): 103-16.
  3. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71(1 Suppl): 343S-8S.
  4. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al, editors. Harrison's principles of internal medicine. 17th ed. New York, NY: McGraw-Hill; 2008.
  5. Darlington LG, Stone TW. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br J Nutr 2001; 85(3): 251-69.
  6. Rennie KL, Hughes J, Lang R, Jebb SA. Nutritional management of rheumatoid arthritis: a review of the evidence. J Hum Nutr Diet 2003; 16(2): 97-109.
  7. Kohno K, Okamoto I, Sano O, Arai N, Iwaki K, Ikeda M, et al. Royal jelly inhibits the production of proinflammatory cytokines by activated macrophages. Biosci Biotechnol Biochem 2004; 68(1): 138-45.
  8. Erem C, Deger O, Ovali E, Barlak Y. The effects of royal jelly on autoimmunity in Graves' disease. Endocrine 2006; 30(2): 175-83.
  9. Mannoor MK, Shimabukuro I, Tsukamotoa M, Watanabe H, Yamaguchi K, Sato Y. Honeybee royal jelly inhibits autoimmunity in SLE-prone NZB x NZW F1 mice. Lupus 2009; 18(1): 44-52.
  10. Gasic S, Vucevic D, Vasilijic S, Antunovic M, Chinou I, Colic M. Evaluation of the immunomodulatory activities of royal jelly components in vitro. Immunopharmacol Immunotoxicol 2007; 29(3-4): 521-36.
  11. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23(5 Suppl 39): S100-S108.
  12. van der Heijde DM, van 't HM, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20(3): 579-81.
  13. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38(1): 44-8.
  14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31(3): 315-24.
Journal of Isfahan Medical School
Volume 31, Issue 252 - Serial Number 252
July and August 2013
Pages 1428-1434

Files

History

  • Receive Date: 31 July 2012
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics